The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 09, 2013
Filed:
Dec. 30, 2011
Jochen G. Salfeld, North Grafton, MA (US);
John A. Mankovich, Andover, MA (US);
Deborah J. Allen, London, GB;
Hendricus R.j.m. Hoogenboom, Hasselt, BE;
Boris Labkovsky, Framingham, MA (US);
Brian T. Mcguinness, Cambridge, GB;
Paul Sakorafas, Newtown Highlands, MA (US);
Michael White, Framingham, MA (US);
Alison J. Wilton, Cambridge, GB;
Zehra Kaymakcalan, Westboro, MA (US);
Andrew J. Roberts, Cambridge, GB;
David Schoenhaut, Clifton, NJ (US);
Tristan J. Vaughan, Cambridge, GB;
Jochen G. Salfeld, North Grafton, MA (US);
John A. Mankovich, Andover, MA (US);
Deborah J. Allen, London, GB;
Hendricus R.J.M. Hoogenboom, Hasselt, BE;
Boris Labkovsky, Framingham, MA (US);
Brian T. McGuinness, Cambridge, GB;
Paul Sakorafas, Newtown Highlands, MA (US);
Michael White, Framingham, MA (US);
Alison J. Wilton, Cambridge, GB;
Zehra Kaymakcalan, Westboro, MA (US);
Andrew J. Roberts, Cambridge, GB;
David Schoenhaut, Clifton, NJ (US);
Tristan J. Vaughan, Cambridge, GB;
Abbott Biotechnology Ltd., Hamilton, BM;
Abstract
Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K=10M or less), a slow off rate for hTNFα dissociation (e.g., K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.